Esophageal cancer is a significant global health concern, ranking as the 11th most common cancer and the 7th leading cause of cancer-related deaths worldwide. In East Asia, particularly China, esophageal squamous cell carcinoma (ESCC) is the predominant type. For patients with locally advanced ESCC, the standard treatment involves neoadjuvant therapy, such as chemotherapy, chemoradiotherapy, or chemoimmunotherapy, followed by curative esophagectomy. However, despite advancements in surgical techniques and perioperative care, severe postoperative complications (SPCs) remain a major issue, impacting patient outcomes and survival.
The Impact of Preoperative Spirometry and Inflammation on ESCC Patients
This study aims to shed light on the often-overlooked issue of preserved ratio impaired spirometry (PRISm) and its impact on ESCC patients undergoing neoadjuvant therapy and surgery. PRISm, characterized by a forced expiratory volume in one second (FEV1) below 80% predicted, with a preserved FEV1/FVC ratio, is a distinct spirometric pattern that affects a significant portion of the population (7-13%) but is often underrecognized.
Systemic inflammation, a key player in surgical recovery and cancer progression, is also a focus of this study. Various inflammation-based hematologic indices, such as the neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and others, have emerged as cost-effective markers of immune imbalance and tumor-promoting inflammation.
The study's unique contribution lies in its exploration of the combined predictive value of preoperative PRISm and systemic inflammatory markers in ESCC patients. By integrating respiratory function and immunoinflammatory status, the researchers aimed to develop a comprehensive risk stratification model.
Unraveling the Impact of PRISm and Inflammation on Short- and Long-Term Outcomes
The study evaluated the impact of PRISm and inflammatory biomarkers on both short-term (SPC incidence) and long-term outcomes (overall survival and recurrence-free survival) in ESCC patients. The results were eye-opening. Patients with preoperative PRISm had a significantly higher incidence of SPCs, with the most common complications being pneumonia, anastomotic leakage, and atrial fibrillation. Multivariate analysis revealed that PRISm and the systemic inflammation response index (SIRI) were independent predictors of SPCs.
The long-term outcomes were equally concerning. Patients with PRISm had significantly poorer overall survival and recurrence-free survival rates compared to those with normal spirometry. The 3-year overall survival rate was 53.1% for the PRISm group, with a median survival time of 44 months, compared to a 78.0% 3-year survival rate for the normal group. Similarly, the 3-year recurrence-free survival rate was 50.1% for the PRISm group, with a median RFS of 39 months, while the normal group achieved a 3-year RFS rate of 81.1%.
Developing Predictive Nomograms for Personalized Clinical Decision-Making
To aid in personalized clinical decision-making and improve perioperative risk stratification, the study developed and validated predictive nomograms. These nomograms, incorporating PRISm, SIRI, and other relevant factors, showed good discriminative performance and calibration, outperforming traditional TNM staging in predicting complications and survival.
The Clinical Significance and Future Directions
The study's findings highlight the importance of routine pulmonary function testing, particularly for older or high-risk surgical candidates. The decrease in FEF50, indicating early small airway dysfunction, may be a crucial factor in postoperative pulmonary complications and long-term survival.
The prognostic significance of systemic inflammatory biomarkers, especially SIRI and lymphocyte-to-monocyte ratio (LMR), was also validated. These markers reflect the complex interplay between inflammation and immune surveillance, and their role in ESCC prognosis is an area of growing interest.
While the study provides robust predictive tools, it also acknowledges its limitations, including the retrospective, single-center design and the need for prospective multicenter validation. Further research is needed to explore the biological mechanisms underlying PRISm-associated inflammation and its impact on tumor progression and treatment resistance.
In conclusion, this study sheds light on the often-overlooked impact of PRISm and systemic inflammation on ESCC patients undergoing neoadjuvant therapy and surgery. The developed nomograms offer a promising tool for personalized risk stratification and clinical decision-making, but further validation is essential to confirm their clinical utility. These findings have the potential to significantly improve the management and outcomes of ESCC patients, and the study's authors believe these tools hold significant potential for clinical translation.
